Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by scarlet1967on Mar 16, 2021 11:55am
121 Views
Post# 32807691

RE:Hard belly fat

RE:Hard belly fatIt looks like the company is gearing up for the lunch of F8. As per the combo oral treatment it is early days even if approved we don't know the efficacy, adverse effects and patient criteria(long lasting HIV drugs so far seems be working best with patients already having stable viral loads for a  year or so and been treated with combination drugs for quite of while) so it's not a sure thing they would be a complete replacement for current drugs  but it's something both THTX and Taimed should monitor and keep in mind before committing to expensive trials imo.
To me along with upcoming catalysts a decent marketing would be a must to get the best possible market reaction.

https://www.theratech.com/career/

qwerty22 wrote: Maybe Scarlett already found this one. It's 8 months old. I would bet Thera made it happen.

https://www.youtube.com/watch?v=T9vaXVru_OQ


<< Previous
Bullboard Posts
Next >>